HeartSciences seeks to bridge today’s “diagnostic gap” in cardiac care by providing effective front-line solutions that assist in the detection of heart disease in at-risk patients. HeartSciences has invested years of R&D focused on advancing the field of electrocardiography through the use of technology to develop new algorithms focused on detecting cardiac conditions not previously available in ECG devices. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device uses an advanced form of signal processing called continuous wavelet transform (CWT) to extract valuable frequency information from the acquired signal and then analyzes this information using artificial intelligence.
HeartSciences initial algorithm provides new information related to a patient’s risk for left ventricular relaxation abnormalities. Most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and LV diastolic dysfunction¹. Assisting physicians in detecting LV dysfunction in a front-line environment can provide for more effective identification of patients that need referral for additional cardiac testing.
¹LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, MD and William C. Little, MD AHA Circ 2012 Feb 14; 125(6): 743–745